The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta‐analysis
Abstract
BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The authors performed comprehensive meta‐analysis to assess the strength of associations between these conditions and the BRAFV600E mutation. METHODS: The authors identified the clinical studies that examined the association of the BRAFV600E mutation in surgical specimens with clinicopathologic outcomes between January 2003 and October 2010 using the Medline database. One hundred thirty‐one relevant studies were hand‐searched. The authors selected 27 studies that included 5655 PTC patients. They calculated the pooled odds ratios (ORs) or risk ratios with 95% confidence intervals (CIs) for each study using a random effect model. RESULTS: The average prevalence rate of the BRAFV600E mutation was 49.4%. In 26 studies, compared with the patients who had the wild‐type BRAF genes, the PTC patients with the BRAFV600E mutation had increased ORs of an extrathyroidal invasion (OR, 2.14; 95% CI, 1.68‐2.73), a lymph node metastasis (OR, 1.54; 95% CI, 1.21‐1.97), and an advanced TNM stage (OR, 2.00; 95% CI, 1.61‐2.49). In 8 studies, patients with the mutation had 2.14‐fold increased risk of recurrent and persistent disease (95% CI, 1.67‐2.74). The associations were generally consistent across the different study populations. CONCLUSIONS: This meta‐analysis demonstrates that the BRAFV600E mutation is closely related to the high‐risk clinicopathological factors and poorer outcome of PTC. The results obtained here suggest that the BRAFV600E mutation should be considered as a poor prognostic marker in PTC and may lead to better management for individual patients. Cancer 2012;. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,403
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
Bellamy, L., Casas, J.-P., Hingorani, A. D., & Williams, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60731-5 · Cited by 3,253
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005
Chen, A. Y., Jemal, A., & Ward, E. M. (2009) · Cancer · doi:10.1002/cncr.24416 · Cited by 988
Xing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
Xing, M., Alzahrani, A. S., Carson, K. A., Viola, D., Elisei, R., Bendlova, B., Yip, L., Mian, C., Vianello, F., Tuttle, R. M., et al. (2013) · JAMA · doi:10.1001/jama.2013.3190 · Cited by 940
Progress in molecular-based management of differentiated thyroid cancer
Xing, M., Haugen, B. R., & Schlumberger, M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60109-9 · Cited by 573
Senescent tumor cells lead the collective invasion in thyroid cancer
Kim, Y. H., Choi, Y. W., Lee, J., Soh, E. Y., Kim, J.-H., & Park, T. J. (2017) · Nature Communications · doi:10.1038/ncomms15208 · Cited by 253
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
Metadata
- Authors
- Kim, T. H., Park, Y. J., Lim, J. A., Ahn, H. Y., Lee, E. K., Lee, Y. J., Kim, K. W., Hahn, S. K., Youn, Y. K., Kim, K. H., Cho, B. Y., & Park, D. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-08-31
- Volume
- 118
- Issue
- 7
- Pages
- 1764-1773
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1538981488
- Cited by
- 400
- References
- 48
- FWCI
- 26.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta‐analysis. https://app.cochat.ai/papers/10.1002/cncr.26500
- The paper
- Kim, T. H., Park, Y. J., Lim, J. A., Ahn, H. Y., Lee, E. K., Lee, Y. J., Kim, K. W., Hahn, S. K., Youn, Y. K., Kim, K. H., Cho, B. Y., & Park, D. J. (2012). The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta‐analysis. Cancer. https://doi.org/10.1002/cncr.26500
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
